Bill Sponsor
House Bill 6092
116th Congress(2019-2020)
Veteran's Prostate Cancer Treatment and Research Act
Active
Active
Passed House on Sep 22, 2020
Overview
Text
Sponsor
Introduced
Mar 5, 2020
Latest Action
Sep 23, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6092
Congress
116
Policy Area
Armed Forces and National Security
Armed Forces and National Security
Primary focus of measure is military operations and spending, facilities, procurement and weapons, personnel, intelligence; strategic materials; war and emergency powers; veterans’ issues. Measures concerning alliances and collective security, arms sales and military assistance, or arms control may fall under International Affairs policy area.
Sponsorship by Party
Republican
Florida
Republican
New Jersey
Republican
North Carolina
Democrat
South Carolina
House Votes (1)
Senate Votes (0)
checkPassed on September 22, 2020
Status
Passed
Type
Voice Vote
Voice Vote
A vote in which the presiding officer states the question, then asks those in favor and against to say "Yea" or "Nay," respectively, and announces the result according to his or her judgment. The names or numbers of senators voting on each side are not recorded.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Summary

Veteran's Prostate Cancer Treatment and Research Act

This bill requires the Department of Veterans Affairs (VA) to implement programs and resources related to the diagnosis and treatment of prostate cancer.

Specifically, the bill requires the VA to establish in its National Surgery Office a national clinical pathway for all stages of prostate cancer that includes specified elements. A clinical pathway is a health care management tool designed around research and evidence-backed practices that provides direction for the clinical care and treatment of a specific episode of a condition or ailment.

The VA must publish the proposed clinical pathway in the Federal Register for public comment. Additionally, the bill requires the VA to publish the established clinical pathway on a public VA website and to update the clinical pathway at least annually.

Under the bill, the VA must submit (1) a plan to establish a comprehensive prostate cancer program, and (2) a plan that provides for continual funding for supporting prostate cancer research through the VA Office of Research and Development. The VA must also establish a program evaluation tool to learn best practices of multidisciplinary disease-based implementation.

Finally, the VA must establish a real-time, actionable, national prostate cancer registry that is accessible to clinicians and researchers.

Text (3)
September 23, 2020
September 22, 2020
March 5, 2020
Actions (12)
09/23/2020
Received in the Senate and Read twice and referred to the Committee on Veterans' Affairs.
09/22/2020
Motion to reconsider laid on the table Agreed to without objection.
09/22/2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4684-4685)
09/22/2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
09/22/2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 6092.
09/22/2020
Considered under suspension of the rules. (consideration: CR H4682-4685)
09/22/2020
Mr. Takano moved to suspend the rules and pass the bill, as amended.
09/17/2020
Ordered to be Reported by Voice Vote.
09/17/2020
Committee Consideration and Mark-up Session Held.
09/10/2020
Committee Hearings Held.
03/05/2020
Referred to the House Committee on Veterans' Affairs.
03/05/2020
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:45:04 PM